Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Lohr

Showing results (41-50 of 56) with videos related to

Pageof 6
Sort By:
Nature Cell Biology|October 22, 2021
Dynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in myelomaJulia Frede, Praveen Anand, Noori Sotudeh, et al.
Nature Communications|November 21, 2025
Remodeling of the immune microenvironment is linked to adverse outcome in pediatric T cell acute lymphoblastic leukemiaCaroline R M Wiggers, Eugene Y Cho, Merve Ozdemir, et al.
Leukemia|May 12, 2018
Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencingGuangwu Guo, Noopur S Raje, Charles Seifer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2021
Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in <i>BRAF</i>-Mutated Multiple MyelomaJohannes M Waldschmidt, Jake A Kloeber, Praveen Anand, et al.
The Prostate|January 27, 2022
Implementation of a prostate cancer-specific targeted sequencing panel for credentialing of patient-derived cell lines and genomic characterization of patient samplesElizabeth H Stover, Coyin Oh, Paula Keskula, et al.
Leukemia|September 19, 2025
The endogenous T cell landscape is reshaped by CAR-T cell therapy and predicts treatment response in multiple myelomaJulia Frede, Julia C Poller, Kayleen Shi, et al.
Blood|November 23, 2020
Single-cell RNA-seq reveals developmental plasticity with coexisting oncogenic states and immune evasion programs in ETP-ALLPraveen Anand, Amy Guillaumet-Adkins, Valeriya Dimitrova, et al.
Science Advances|July 26, 2023
Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineeringLi Li, Vakul Mohanty, Jinzhuang Dou, et al.
Blood Advances|December 3, 2024
Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myelomaAndrew J Yee, Jacob P Laubach, Erica L Campagnaro, et al.
Cell Reports|April 6, 2017
The Mutational Landscape of Circulating Tumor Cells in Multiple MyelomaYuji Mishima, Bruno Paiva, Jiantao Shi, et al.
Pageof 6

Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
Nature Cell Biology|October 22, 2021
Dynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in myelomaJulia Frede, Praveen Anand, Noori Sotudeh, et al.
Nature Communications|November 21, 2025
Remodeling of the immune microenvironment is linked to adverse outcome in pediatric T cell acute lymphoblastic leukemiaCaroline R M Wiggers, Eugene Y Cho, Merve Ozdemir, et al.
Leukemia|May 12, 2018
Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencingGuangwu Guo, Noopur S Raje, Charles Seifer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2021
Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in <i>BRAF</i>-Mutated Multiple MyelomaJohannes M Waldschmidt, Jake A Kloeber, Praveen Anand, et al.
The Prostate|January 27, 2022
Implementation of a prostate cancer-specific targeted sequencing panel for credentialing of patient-derived cell lines and genomic characterization of patient samplesElizabeth H Stover, Coyin Oh, Paula Keskula, et al.
Leukemia|September 19, 2025
The endogenous T cell landscape is reshaped by CAR-T cell therapy and predicts treatment response in multiple myelomaJulia Frede, Julia C Poller, Kayleen Shi, et al.
Blood|November 23, 2020
Single-cell RNA-seq reveals developmental plasticity with coexisting oncogenic states and immune evasion programs in ETP-ALLPraveen Anand, Amy Guillaumet-Adkins, Valeriya Dimitrova, et al.
Science Advances|July 26, 2023
Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineeringLi Li, Vakul Mohanty, Jinzhuang Dou, et al.
Blood Advances|December 3, 2024
Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myelomaAndrew J Yee, Jacob P Laubach, Erica L Campagnaro, et al.
Cell Reports|April 6, 2017
The Mutational Landscape of Circulating Tumor Cells in Multiple MyelomaYuji Mishima, Bruno Paiva, Jiantao Shi, et al.
Pageof 6